更正：B7-H3 CAR-T 细胞清除肝内胆管癌并诱导持久应答
Correction: B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞在胆管癌中的研究进展
英文原题：Research progress of T cells in cholangiocarcinoma.
查看英文原题
Research progress of T cells in cholangiocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胆管癌（CCA）是一种恶性肿瘤，通常难以早期发现，且往往预后不良。近年来，免疫治疗在 CCA 治疗中的潜在应用引起了越来越多的研究兴趣。T 细胞作为免疫系统的重要组成部分，在胆管癌的免疫监视和治疗中发挥着重要作用。本文综述了胆管癌患者中 T 细胞相关的研究进展，包括其在肿瘤微环境中的分布、功能状态以及与患者预后的相关性。进一步讨论了针对 T 细胞的免疫治疗策略在 CCA 治疗中的潜在应用和挑战，并展望了未来的研究方向。更深入地理解 T 细胞在胆管癌中的作用可以指导临床治疗策略的制定，从而提高患者的生存率和生活质量。最后，我们探讨了 T 细胞胆管癌免疫治疗的潜在风险和副作用。
展开英文摘要原文
Cholangiocarcinoma (CCA), a malignant tumor, is typically challenging to detect early and often results in a poor prognosis. In recent years, research interest has grown in the potential application of immunotherapy for CCA treatment. T cells, as a crucial component of the immune system, play a significant role in immune surveillance and therapy for cholangiocarcinoma.
This article provides a review of the research advancements concerning T cells in cholangiocarcinoma patients, including their distribution, functional status, and correlation with patient prognosis within the tumor microenvironment.
It further discusses the potential applications and challenges of immunotherapy strategies targeting T cells in CCA treatment and anticipates future research directions. A more profound understanding of T cells' role in cholangiocarcinoma can guide the development of clinical treatment strategies, thereby enhancing patient survival rates and quality of life.
Finally, we explored the potential risks and side effects of immunotherapy for T-cell cholangiocarcinoma.
论文信息
- 作者
- Wang Z、Dai Y、Zhou Y、Wang Y、Chen P、Li Y、Zhang Y、Wang X
- 第一作者单位
- Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.China
- 通讯作者单位
- Department of Clinical Laboratory, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40070825 · DOI 10.3389/fimmu.2025.1453344
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →